PhaseV, a developer of software and machine learning for clinical trial optimisation, announced on Monday that it has partnered with Alimentiv Inc, a gastrointestinal (GI) contract research organisation.

The partnership is aimed at supporting the optimal design and implementation of advanced adaptive clinical trials for a range of GI conditions. These trials will focus on inflammatory bowel disease (IBD), coeliac disease, eosinophilic gastrointestinal disease (EGID) and other related disorders.

According to PhaseV, the partnership has the potential to accelerate the development of new GI therapies by using adaptive trial methodologies that improve efficiency and results for patients facing these challenging conditions.